Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(19):1411; doi:10.1093/jnci/96.19.1411
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zielinski, S. L.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Money Matters: How Cost-Effectiveness Studies Are Done

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

No one likes to admit that money matters in health care, but it does. One tool for comparing the cost of treatments or interventions, such as chemoprevention, is the cost-effectiveness study.

A cost-effectiveness study compares the incremental cost of treatment to the incremental benefit. To determine cost . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Despite Positive Studies, Popularity of Chemoprevention Drugs Increasing Slowly
Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1410-1412. [Extract] [Full Text] [PDF]